Forte Biosciences, Inc. (FBRX) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Forte Biosciences is a clinical-stage biopharmaceutical company focused on developing FB102, a proprietary anti-CD122 monoclonal antibody for autoimmune indications. The company has no approved products and has not generated any revenue from product sales. Phase 1 healthy volunteer cohorts for FB102 have been completed, and the company is advancing into patient-based studies, with a celiac disease trial expected to initiate in Q3 2024.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(12.5) million | $(8.9) million | $(19.9) million | $(15.6) million |
| Net Loss Per Share | $(0.27) | $(0.42) | $(0.43) | $(0.74) |
| Operating Expenses | $12.8 million | $9.0 million | $20.6 million | $15.9 million |
| Cash & Equivalents (End of Period) | $24.5 million (as of June 30, 2024) | |||
| Accumulated Deficit | $138.5 million (as of June 30, 2024) | |||
| Net Cash Used in Operating Activities | N/A | $(12.6) million | $(10.7) million |
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses increased by $3.8 million (42%) for the three months ended June 30, 2024, compared to the same period in 2023. This was primarily driven by a $5.2 million increase in General and Administrative (G&A) expenses due to higher legal and professional fees.
- Decreased R&D Expenses: Research and Development expenses decreased by $1.4 million for the quarter, primarily due to a reduction in manufacturing costs, partially offset by increased payroll expenses.
- Legal Accruals: Accrued liabilities increased significantly, including a $1.7 million accrual for estimated legal fees related to the Camac Fund litigation settlement discussions.
- Cash Burn: Net cash used in operating activities increased to $12.6 million for the six months ended June 30, 2024, compared to $10.7 million in the prior year period.
Guidance, Outlook, Risks, and Contingencies
- Clinical Outlook: Management anticipates initiating patient-based studies for celiac disease in Q3 2024, with top-line results expected in Q2 2025. FB102 is also being evaluated for vitiligo, Type 1 diabetes, GvHD, and alopecia areata.
- Liquidity: As of June 30, 2024, the company held $24.5 million in cash and cash equivalents. Management believes this is sufficient to fund operations for at least 12 months from the filing date. However, the company will require additional capital to complete development and may need to raise funds through equity or debt offerings.
- Legal Contingency: A significant legal proceeding with Camac Fund LP regarding a 2023 private placement and board election is ongoing. While a settlement agreement was reached in June 2024, the court declined to approve it in July 2024. The company has accrued $1.7 million for estimated legal fees and paid $364,000. The company intends to vigorously defend against the claims if litigation proceeds.
- Nasdaq Compliance: The company is currently non-compliant with Nasdaq's minimum bid price requirement ($1.00). It has received an extension until September 9, 2024, to regain compliance. Failure to comply could result in delisting. A reverse stock split proposal is pending stockholder approval.
- Financing Restrictions: The company's Form S-3 shelf registration statement expired in June 2024. While an "at-the-market" (ATM) facility exists, the company is currently restricted in its ability to sell securities under Form S-3 due to public float limitations (must be under $75 million).
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $24.5 million cash balance against the projected burn rate of ~$12.6 million per six months to confirm the 12-month liquidity assertion.
- Legal Resolution: Monitor the status of the Camac Fund litigation following the court's rejection of the settlement; further legal costs or adverse rulings could materially impact cash reserves.
- Nasdaq Status: Confirm whether the company regains compliance with the $1.00 minimum bid price by September 9, 2024, or if a reverse stock split is approved to avoid delisting.
- Capital Raising: Assess the company's ability to secure new financing given the expired S-3 shelf and current market conditions, as additional capital is required to advance FB102 beyond Phase 1.
- Expense Trends: Track the trajectory of G&A expenses, which spiked significantly in Q2 2024 due to legal fees, to determine if this is a one-time event or a new baseline.